Underuse of Effective Cardiac Medications Among Women, Middle-Aged Adults, and Racial/Ethnic Minorities With Coronary Artery Disease (from the National Health and Nutrition Examination Survey 2005 to 2014)

      Given the proven effectiveness of several cardiac medications for patients with coronary artery disease (CAD), we examined the national use of 4 classes of effective medications, overall and by age, sex, and race/ethnicity in 2005 to 2014. We used data from the National Health and Nutrition Examination Survey, including a self-reported diagnosis of CAD and independently verified medication use. Weighting procedures extrapolated our data to the adult US population with CAD. Analyses included 1,789 US adults aged ≥45 years with a history of CAD. The average age of this population was 68 years; 40% were women and 79% were non-Hispanic whites. In 2005 to 2014, 53.2% (standard error [SE] = 1.5) reported use of angiotensin-converting enzyme inhibitor/angiotensin receptor blockers, 58.5% (SE = 1.5) β blockers, and 67.2% (SE = 1.4) statins. Two of these medications were used by 64.1% (SE = 1.5) of the study population and all 3 by 29.1% (SE = 1.3). In 2011 to 2014, 68.5% (SE = 2.4) of American adults with a history of CAD reported use of aspirin. The use of statins increased from 63.1% in 2005/2006 to 76.8% in 2013/2014. Adults aged 45 to 64 years old, women, and racial/ethnic minorities had lower use of effective cardiac medications compared with older adults, men, and non-Hispanic whites. In conclusion, the use of statins, but not other medications, has increased over the past 10 years among American adults with previously diagnosed CAD. Continued targeted efforts are needed to increase the receipt of effective cardiac medications among all US adults with CAD, especially those aged 45 to 64 years, women, and racial/ethnic minorities.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Smith S.C.
        • Benjamin E.J.
        • Bonow R.O.
        • Braun L.T.
        • Creager M.A.
        • Franklin B.A.
        • Gibbons R.J.
        • Grundy S.M.
        • Hiratzka L.F.
        • Jones D.W.
        AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association.
        J Am Coll Cardiol. 2011; 58: 2432-2446
        • Amann U.
        • Kirchberger I.
        • Heier M.
        • Golüke H.
        • von Scheidt W.
        • Kuch B.
        • Peters A.
        • Meisinger C.
        Long-term survival in patients with different combinations of evidence-based medications after incident acute myocardial infarction: results from the MONICA/KORA Myocardial Infarction Registry.
        Clin Res Cardiol. 2014; 103: 655-664
        • Rasmussen J.N.
        • Chong A.
        • Alter D.A.
        Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction.
        JAMA. 2007; 297: 177-186
        • Shah N.S.
        • Huffman M.D.
        • Ning H.
        • Lloyd-Jones D.M.
        Trends in myocardial infarction secondary prevention: the National Health and Nutrition Examination Surveys (NHANES), 1999–2012.
        J Am Heart Assoc. 2015; 4: e001709
        • Setoguchi S.
        • Glynn R.J.
        • Avorn J.
        • Levin R.
        • Winkelmayer W.C.
        Ten-year trends of cardiovascular drug use after myocardial infarction among community-dwelling persons ≥65 years of age.
        Am J Cardiol. 2007; 100: 1061-1067
        • Choudhry N.K.
        • Setoguchi S.
        • Levin R.
        • Winkelmayer W.C.
        • Shrank W.H.
        Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients.
        Pharmacoepidemiol Drug Saf. 2008; 17: 1189-1196
        • Nelson A.R.
        • Smedley B.D.
        • Stith A.Y.
        Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care.
        National Academies Press, Washington (DC)2002
        • Lee H.Y.
        • Cooke C.E.
        • Robertson T.A.
        Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge.
        J Manag Care Pharm. 2008; 14: 271-280
        • Vaccarino V.
        • Rathore S.S.
        • Wenger N.K.
        • Frederick P.D.
        • Abramson J.L.
        • Barron H.V.
        • Manhapra A.
        • Mallik S.
        • Krumholz H.M.
        Sex and racial differences in the management of acute myocardial infarction, 1994 through 2002.
        N Engl J Med. 2005; 353: 671-682
        • Centers for Disease Control and Prevention (CDC)
        • National Center for Health Statistics (NCHS)
        National Health and Nutrition Examination Survey Data.
        (October 30, 2015)2016
        • Centers for Disease Control and Prevention (CDC)
        • National Center for Health Statistics (NCHS)
        National Health and Nutrition Examination Survey Questionnaire, 2015.
        • Davis W.W.
        Examining Trends and Averages Using Combined Cross-Sectional Survey Data from Multiple Years.
        UCLA Center for Health Policy Research, Los Angeles, California2007
        • Walter S.
        • Tiemeier H.
        Variable selection: current practice in epidemiological studies.
        Eur J Epidemiol. 2009; 24: 733-736
        • U.S. Department of Health and Human Services
        National Hospital Discharge Survey, Public Use Data File Documentation, 2012.
        • Smith S.C.
        • Blair S.N.
        • Bonow R.O.
        • Brass L.M.
        • Cerqueira M.D.
        • Dracup K.
        • Fuster V.
        • Gotto A.
        • Grundy S.M.
        • Miller N.H.
        AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology.
        J Am Coll Cardiol. 2001; 38: 1581-1583
        • Lewis W.R.
        • Ellrodt A.G.
        • Peterson E.
        • Hernandez A.F.
        • LaBresh K.A.
        • Cannon C.P.
        • Pan W.
        • Fonarow G.C.
        Trends in the use of evidence-based treatments for coronary artery disease among women and the elderly: findings from the get with the guidelines quality-improvement program.
        Circ Cardiovasc Qual Outcomes. 2009; 2: 633-641
        • Chen H.
        • Saczynski J.S.
        • Lapane K.L.
        • Kiefe C.I.
        • Goldberg R.J.
        Adherence to evidence-based secondary prevention pharmacotherapy in patients after an acute coronary syndrome: a systematic review.
        Heart Lung. 2015; 44: 299-308
        • Gencer B.
        • Rodondi N.
        • Auer R.
        • Räber L.
        • Klingenberg R.
        • Nanchen D.
        • Carballo D.
        • Vogt P.
        • Carballo S.
        • Meyer P.
        • Matter C.M.
        • Windecker S.
        • Lüscher T.F.
        • Mach F.
        Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes.
        Eur J Intern Med. 2015; 26: 56-62
        • Claxton A.J.
        • Cramer J.
        • Pierce C.
        A systematic review of the associations between dose regimens and medication compliance.
        Clin Ther. 2001; 23: 1296-1310
        • Sanz G.
        • Fuster V.
        Prevention: polypills for cardiovascular prevention: a step forward?.
        Nat Rev Cardiol. 2013; 10: 683-684
        • Cole J.A.
        • Brennan A.L.
        • Ajani A.E.
        • Yan B.P.
        • Duffy S.J.
        • Loane P.
        • Reid C.M.
        • Yudi M.B.
        • New G.
        • Black A.
        • Shaw J.
        • Clark D.J.
        • Andrianopoulos N.
        Cardiovascular medication use following percutaneous coronary intervention: the Australian experience.
        Cardiovasc Ther. 2014; 32: 47-51
        • Niederdeppe J.
        • Byrne S.
        • Avery R.J.
        • Cantor J.
        Direct-to-consumer television advertising exposure, diagnosis with high cholesterol, and statin use.
        J Gen Intern Med. 2013; 28: 886-893
        • National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
        Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
        Circulation. 2002; 106: 3143-3421
        • Williams P.
        Age discrimination in the delivery of health care services to our elders.
        Marquette Elder's Advisor. 2009; 11: 1-46
        • Yarzebski J.
        • Bujor C.F.
        • Goldberg R.J.
        • Spencer F.
        • Lessard D.
        • Gore J.M.
        A community-wide survey of physician practices and attitudes toward cholesterol management in patients with recent acute myocardial infarction.
        Arch Intern Med. 2002; 162: 797-804
        • Kantor E.D.
        • Rehm C.D.
        • Haas J.S.
        • Chan A.T.
        • Giovannucci E.L.
        Trends in prescription drug use among adults in the United States from 1999–2012.
        JAMA. 2015; 314: 1818-1830
        • Egan B.M.
        • Li J.
        • Shatat I.F.
        • Fuller J.M.
        • Sinopoli A.
        Closing the gap in hypertension control between younger and older adults: National Health and Nutrition Examination Survey (NHANES) 1988 to 2010.
        Circulation. 2014; 129: 2052-2061
        • Martin L.R.
        • Williams S.L.
        • Haskard K.B.
        • Dimatteo M.R.
        The challenge of patient adherence.
        Ther Clin Risk Manag. 2005; 1: 189-199
        • Johansen M.E.
        • Hefner J.L.
        • Foraker R.E.
        Antiplatelet and statin use in US patients with coronary artery disease categorized by race/ethnicity and gender, 2003 to 2012.
        Am J Cardiol. 2015; 115: 1507-1512
        • Hackam D.G.
        • Leiter L.A.
        • Yan A.T.
        • Yan R.T.
        • Mendelsohn A.
        • Tan M.
        • Zavodni L.
        • Chen R.
        • Tsang J.L.
        • Kundi A.
        Missed opportunities for the secondary prevention of cardiovascular disease in Canada.
        Can J Cardiol. 2007; 23: 1124-1130